Showing 2771-2780 of 3010 results for "".
- Mirvaso Approved by the European Commissionhttps://practicaldermatology.com/news/20140226-mirvaso_approved_by_the_european_commission/2459330/The European Commission has granted marketing authorization in Europe for Galderma's Mirvaso (brimonidine) 3 mg/g gel. Mirvaso, an alpha-2 adrenergic receptor agonist that acts rapidly and can last for up to 12 hours, is indicated for the symptomatic tr
- Onset Dermatologics Launches New Strength of Minocinhttps://practicaldermatology.com/news/20140225-onset_dermatologics_launches_new_strength_of_minocin/2459333/Onset Dermatologics launced a 75mg strength of Minocin (minocycline hydrochloride) Pellet-Filled Capsules, a tetracycline class antibiotic medicine used to treat infections caused by bacteria. Minocin may be used along with other agents in the treatment of severe acne.
- Registration Open for Dermatology Nurses' Associaion's 32nd Annual Conventionhttps://practicaldermatology.com/news/20140221-registration_open_for_dermatology_nurses_associaions_32nd_annual_convention/2459335/The Dermatology Nurses' Association's 32nd Annual Convention will be held Thursday, May 1, 2014 through Sunday, May 4, 2014 at the Walt Disney World Swan and Dolphin Hotel, in Orlando, FL. Online registration is
- Eclipse Sun Launches New Line of Sun Protective Clothing for Babies and Kidshttps://practicaldermatology.com/news/20140220-eclipse_sun_launches_new_line_of_sun_protective_clothing_for_babies_and_kids/2459336/Eclipse Sun Products announced the introduction of its new line of sun protective clothing made especially for babies and kids. The
- Kerecis Receives US Patent for Fish-Skin-Based Tissue Regeneration Technologyhttps://practicaldermatology.com/news/20140219-kerecis_receives_us_patent_for_fish-skin-based_tissue_regeneration_technology/2459340/A US patent was awarded to Kerecis Limited for the use of fish skin in medical applications. The Kerecis material consists of sheets of intact, decellulariz
- Support Camp Discovery: Follow Us on Twitterhttps://practicaldermatology.com/news/20140130-support_camp_discovery_follow_us_on_twitter/2459354/Practical Dermatology® is excited to announce that we'll donate 20 cents for every new Twitter follower from Jan. 31, 2014 through March 14, 2014* to Camp Discovery. Simply follow @Practical_Derm on Twitte
- CeraVe Launches Two Skin Care Productshttps://practicaldermatology.com/news/20140123-cerave_launches_two_skin_care_products/2459361/CeraVe has introduced the CeraVe Eye Repair Cream and CeraVe Intensive Stretch Marks Cream. The Eye Repair Cream combines three essential ceramides, to help repair and restore the delicate barrier around the eyes, with hydrating hyaluronic acid to help diminish fine lines and wrinkles. The Intensive
- Alma Lasers Debuts its 2014 Webinar Serieshttps://practicaldermatology.com/news/20140116-alma_lasers_debuts_its_2014_webinar_series/2459372/In a complimentary webinar series, industry experts will showcase their success building local market awareness to drive practice results. Spearheaded by Alma Lasers , the informative ses
- Daniel Siegel, MD Appointed to Board of Directors for Caliber Imaging & Diagnosticshttps://practicaldermatology.com/news/20140113-daniel_siegel_md_appointed_to_cabilber_imaging__diagnostics_board_of_directors/2459374/Caliber Imaging & Diagnostics, formerly Lucid, Inc., appointed Daniel Mark Siegel, MD to its Board of Directors, effective immediately. This increases the number of Board members to eight. Dr. Siegel is Clinical Professor of Dermatology at SUNY Downstate Medical Center (State Univ
- NeXeption, LLC Forms New Company Alexar Therapeutics, Inc. to Develop Novel LXR Agonist Portfolio for Dermatologic Indicationshttps://practicaldermatology.com/news/20140102-nexeption_llc_forms_new_company_alexar_therapeutics_inc_to_develop_novel_lxr_agonist_portfolio_for_dermatologic_indications/2459383/NeXeption, LLC, a biopharmaceutical management company that brings together product opportunities, management expertise and funding to reach compelling partnership milestones, has secured $21.5 million in Series A financing to form Alexar Therapeutic